2 drug(s) with this reaction
776 total reports
Therapeutic Product Effect Decreased has been reported as an adverse reaction across 2 drug(s) manufactured by Chattem Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 776 adverse event reports mention therapeutic product effect decreased in connection with Chattem Inc products.
This page provides a breakdown of which Chattem Inc drugs are most commonly associated with therapeutic product effect decreased, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Chattem Inc drugs have therapeutic product effect decreased listed in their FDA adverse event reports, sorted by report count:
In addition to therapeutic product effect decreased, the following adverse reactions have been reported across Chattem Inc's drug portfolio:
2 drug(s) manufactured by Chattem Inc have therapeutic product effect decreased listed in their FDA adverse event reports: TRIAMCINOLONE ACETONIDE, DOXYLAMINE SUCCINATE.
There are a combined 776 reports of therapeutic product effect decreased across 2 Chattem Inc drug(s) in the FDA adverse event database.